Budgetary Impact of Advanced Therapy Products in the Unified Health System

Resumo

We sought to map the main advanced therapy products approved by reference heal-th agencies to assess the potential impact of incorporation into the Unified Health System. To this end, we defined the price by the methodology applied by CMED for products with molecules new and therapeutic gains and the demand was based on the incidence of diseases, following population growth. The impact estimations resulted between R$16.6 and R$53.0 billion for the five years after incorporation scenarios, providing relevant subsidies for decision-making agents.